Following a Good Start to the Year Shire Reaffirms Full Year 2008 Financia...(ts not included in the above calculation...)

3 months to March 31, 2008 2007

No. of shares No. of

Millions(1) shares

Millions(1)

Stock options out of the money 12.4 10.3

(1) For the three months ended March 31, 2008 and the three months ended March 31, 2007, certain stock options have been excluded from the calculation of diluted EPS because their exercise prices exceeded Shire plc's average share price during the calculation period.

Unaudited US GAAP results for the three months to March 31, 2008 Selected Notes to the US GAAP Financial Statements (continued)

(2) Analysis of revenues

3 months to March 31, 2008 2007 2008 2008

% % of total

$M $M change revenue

Net product sales:

Specialty Pharmaceuticals ("Specialty")

ADHD

ADDERALL XR 261.5 249.1 5% 37%

VYVANSE 54.4 - - 8%

DAYTRANA 20.3 11.9 71% 3%

336.2 261.0 29% 48%

GI

PENTASA 44.2 43.8 1% 6%

LIALDA / MEZAVANT 27.2 - - 4%

71.4 43.8 63% 10%

Renal

FOSRENOL 36.2 22.8 59% 5%

DYNEPO 6.7 - - 1%

'/>"/>